CareDx, Inc. (CDNA)
| Market Cap | 2.08B +91.5% |
| Revenue (ttm) | 412.82M +19.2% |
| Net Income | -8.19M |
| EPS | -0.16 |
| Shares Out | 51.66M |
| PE Ratio | n/a |
| Forward PE | 49.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,473,538 |
| Open | 36.40 |
| Previous Close | 29.75 |
| Day's Range | 35.50 - 40.38 |
| 52-Week Range | 10.96 - 40.34 |
| Beta | 2.43 |
| Analysts | Buy |
| Price Target | 29.60 (-26.61%) |
| Earnings Date | Jul 30, 2026 |
About CDNA
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about dist... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price target is $29.6, which is a decrease of -26.61% from the latest price.
News
CareDx price target raised to $45 from $28 at BTIG
BTIG raised the firm’s price target on CareDx (CDNA) to $45 from $28 and keeps a Buy rating on the shares. The firm notes shares of CareDx are up 25%…
Craig-Hallum ups CareDx price target after ‘quite favorable’ Medicare LCD
Craig-Hallum raised the firm’s price target on CareDx (CDNA) to $35 from $26 and keeps a Hold rating on the shares after MolDX issued the updated Local Coverage Decision for…
CareDx announces finalization of Medicare Local Coverage Determination process
CareDx (CDNA) announced the finalization of the Medicare Local Coverage Determination process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across...
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report fi...
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization o...
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful comp...
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx showcases precision medicine diagnostics at ATC 2026
CareDx (CDNA) announced its participation at the American Transplant Congress 2026, taking place June 20-24 in Boston, Massachusetts. Real-world clinical use and scientific advancements involving Allo...
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx announces second KOAR analysis published in JASN
The company states: “CareDx (CDNA) announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry, a landmark multi-center study, in the Journal of the American Socie...
CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and an equity plan amendment, with all proposals approved by majority vote. No shareholder questions were received, and final vote results will be published by June 17, 2026.
CareDx Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a strategic shift to precision diagnostics, highlighted by the Naveris acquisition and divestiture of lab products. Key growth drivers include new MRD indications, AlloHeme's upcoming launch, and workflow optimization, with robust financial targets and operational improvements supporting long-term profitability.
CareDx Proxy statement: Proxy filing
CareDx filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.
CareDx Transcript: Jefferies Global Healthcare Conference 2026
Strong Q1 performance with 39% revenue growth led to raised guidance for 2024. Pipeline expansion, including the Naveris acquisition and AlloHeme development, positions the company for leadership in precision diagnostics and oncology MRD, with robust digital integration and targeted commercial strategies.
CareDx denied request to Supreme Court to revive Natera award
A writ of certiorari was denied by the U.S. Supreme Court in the case of CareDx (CDNA) v. Natera (NTRA), meaning that the Court has declined to hear the appeal,…
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx announces dismissal of 2021 Qui Tam Suit
CareDx (CDNA) announced the dismissal of a qui tam action filed against the Company. On April 23, 2026, the United States District Court for the Eastern District of New York…
CareDx Announces Dismissal of 2021 Qui Tam Suit
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinica...
CareDx price target raised to $28 from $26 at BTIG
BTIG raised the firm’s price target on CareDx (CDNA) to $28 from $26 and keeps a Buy rating on the shares. The company has announced many positive updates on its…
CareDx files automatic mixed securities shelf
17:08 EDT CareDx (CDNA) files automatic mixed securities shelf
CareDx to acquire Naveris for $160M up-front, $100M in revenue milestones
The Transplant Company announced it has entered into a definitive agreement to acquire Naveris. The transaction is an extension of CareDx’s (CDNA) strategy to focus on its U.S. Precision Medicine…
CareDx raises FY26 revenue view to $447M-$465M from $420M-$444M
Consensus $437.43M. The Company now expects full year 2026 adjusted EBITDA to be in the range of $43 million to $57 million.
CareDx Earnings Call Transcript: Q1 2026
Q1 revenue grew 39% year-over-year, driven by strong testing and digital solutions growth. The company divested its lab products business and acquired Navoris, expanding into viral-mediated cancer MRD with a differentiated, Medicare-covered platform. 2026 guidance was raised, with no Navoris contribution included.